Skip to main content

Site notifications

Notice for ivosidenib (Servier Laboratories Australia Pty Ltd)

Active ingredients
ivosidenib
Date of review outcome
Lapse date
Type
Priority review
Indication
TIBSOVO monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation, who were previously treated by at least one prior line of systemic therapy
Therapeutic area
Oncology

Help us improve the Therapeutic Goods Administration site